Patent cliffs limit GLP-1 long-term upside
Eli Lilly and GLP-1 drug developers face severe terminal value risks as key patents expire and generic alternatives commoditize the market.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.